Navidea Biopharmaceuticals, Inc. NAVBQ
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 8.10K | 65.60K | 65.60K | 115.30K | 204.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.10K | 65.60K | 65.60K | 115.30K | 204.20K |
| Cost of Revenue | 184.40K | 184.90K | 184.90K | 134.90K | 500.00 |
| Gross Profit | -176.30K | -119.20K | -119.20K | -19.50K | 203.80K |
| SG&A Expenses | 4.82M | 4.75M | 5.36M | 6.37M | 6.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.45M | 11.00M | 11.51M | 11.96M | 12.12M |
| Operating Income | -10.44M | -10.94M | -11.45M | -11.84M | -11.92M |
| Income Before Tax | -12.06M | -13.67M | -15.18M | -15.35M | -12.06M |
| Income Tax Expenses | -- | -- | -- | 0.00 | 16.00K |
| Earnings from Continuing Operations | -12.06 | -13.67 | -15.18 | -15.35 | -12.08 |
| Earnings from Discontinued Operations | 7.43M | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -4.63M | -13.67M | -15.18M | -15.35M | -12.08M |
| EBIT | -10.44M | -10.94M | -11.45M | -11.84M | -11.92M |
| EBITDA | -10.34M | -10.84M | -11.35M | -11.75M | -11.83M |
| EPS Basic | -0.28 | -0.50 | -0.56 | -0.57 | -0.40 |
| Normalized Basic EPS | -0.17 | -0.19 | -0.23 | -0.25 | -0.25 |
| EPS Diluted | -0.28 | -0.50 | -0.56 | -0.57 | -0.40 |
| Normalized Diluted EPS | -0.17 | -0.19 | -0.23 | -0.25 | -0.25 |
| Average Basic Shares Outstanding | 144.01M | 126.03M | 123.59M | 121.37M | 120.76M |
| Average Diluted Shares Outstanding | 144.01M | 126.03M | 123.59M | 121.37M | 120.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |